Dihydroeponemycin
Dihydroeponemycin, an analogue of the antitumor and antiangiogenic natural product eponemycin, selectively targets the 20S proteasome. Dihydroeponemycin covalently modifies a subset of catalytic proteasomal subunits, binding preferentially to the IFN-gamma-inducible subunits LMP2 and LMP7. Dihydroeponemycin-mediated proteasome inhibition induces a spindle-like cellular morphological change and apoptosis[1].
Product Specifications
CAS Number
126463-64-7
UNSPSC
12352005
Hazard Statement
H302
Target
Apoptosis; Proteasome
Type
Reference compound
Related Pathways
Apoptosis; Metabolic Enzyme/Protease
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/dihydroeponemycin.html
Solubility
10 mM in DMSO
Smiles
CC(C)CCCCC(N[C@@H](CO)C(N[C@@H](CC(C)C)C([C@]1(CO1)CO)=O)=O)=O
Molecular Formula
C20H36N2O6
Molecular Weight
400.51
Precautions
P264-P270-P330-P501
References & Citations
[1]Meng L, et al. Eponemycin exerts its antitumor effect through the inhibition of proteasome function. Cancer Res. 1999;59 (12) :2798-2801.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Reagecon Spectrophotometry Holmium Oxide Solution UV and Visible Wavelength Standard 240nm to 640nm
